Search results for "complication"

showing 10 items of 2051 documents

FFR in a Bypass

2016

FFR can be used to determine whether by-pass lesions are significant. In this case, an additional complication was the fact that the lesion was placed at the ostium of the graft: in this case, it is important to retract the guiding catheter to avoid wedging.

Lesionmedicine.medical_specialtyOstiumsurgical procedures operativebusiness.industrymedicineCoronary artery lesionfood and beveragesGuiding cathetermedicine.symptomComplicationbusinessSurgery
researchProduct

Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients

2011

INTRODUCTION: Differentiation between steatosis and non-alcoholic steatohepatitis (NASH) in non-alcoholic fatty liver disease (NAFLD) is important as NASH progress to cirrhosis. No specific laboratory/imaging technique exists either to diagnose NASH or to select patients for liver biopsy. PATIENTS AND METHODS: We evaluated serum ferritin and the features of metabolic syndrome with respect to histological inflammation and/or fibrosis in NAFLD patients. The Kleiner scoring system was used to classify NAFLD in consecutive liver biopsies. One hundred and eleven patients: median age 52.6, 64 males, obesity 62, diabetes mellitus (DM) 58, arterial hypertension 26 and hyperlipidaemia 40%. RESULTS: …

Liver CirrhosisAdultMaleBiopsyHyperlipidemiasFatty Liver/blood/diagnosis/etiology/pathologyRisk AssessmentSeverity of Illness IndexHepatitisBody Mass IndexDiabetes ComplicationsYoung AdultNon-alcoholic Fatty Liver DiseasePredictive Value of TestsRisk FactorsNAFLDLondonMetabolic Syndrome X/blood/*complicationsHumansAspartate AminotransferasesObesityBiological Markers/bloodliver fibrosisAgedMetabolic SyndromeInflammationFerritinChi-Square DistributionPatient SelectionNASHHepatitis/blood/complications/*diagnosisMiddle AgedFibrosisFatty LiverLiver Cirrhosis/blood/*diagnosis/etiologyNomogramsLogistic ModelsHyperlipidemias/blood/complicationsHypertension/blood/complicationsFerritinsHypertensionFerritin; Fibrosis; Inflammation; NAFLD; NASHAspartate Aminotransferases/bloodFemaleDiabetes Complications/blood/diagnosis/etiologyObesity/complicationsBiomarkersFerritins/*blood
researchProduct

Transjugular intrahepatic portosystemic shunt (TIPS) complications: what diagnostic radiologists should know

2022

Transjugular intrahepatic portosystemic shunt (TIPS) is an effective therapy for portal hypertension complications and can successfully treat variceal bleeding and refractory ascites. Although TIPS is relatively safe, procedural- or shunt-related morbidity can reach 20%, and procedural complications have a fatality rate of 2%. Delayed recognition and treatment of TIPS complications can lead to life-threatening clinical scenarios. Complications can vary from stent migration or malpositioning to nontarget organ injury, TIPS dysfunction, encephalopathy, or liver failure. This review aims to outline the role of diagnostic radiology in assessing post-TIPS complications.[GRAPHICS].

Liver CirrhosisComplicationsRadiological and Ultrasound TechnologyUrologyGastroenterologyEsophageal and Gastric VaricesTransjugular intrahepatic portosystemic shuntImagingTreatment OutcomeHepatic EncephalopathyRadiologistsTIPSHumansRadiology Nuclear Medicine and imagingPortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhageAbdominal Radiology
researchProduct

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

2007

The effect of achieving a sustained virological response (SVR) following interferon-α (IFNα) treatment on the clinical outcomes of patients with HCV-related cirrhosis is unknown. In an attempt to assess the risk of liver-related complications, HCC and liver-related mortality in patients with cirrhosis according to the response to IFNα treatment, a retrospective database was developed including all consecutive patients with HCV-related, histologically proven cirrhosis treated with IFNα monotherapy between January 1992 and December 1997. SVR was an undetectable serum HCV-RNA by PCR 24 weeks after IFNα discontinuation. HCC was assessed by ultrasound every 6 months. Independent predictors of al…

Liver CirrhosisMaleANTIVIRAL TREATMENTMultivariate analysisCirrhosisHepacivirusdrug therapy/mortality/virologyGastroenterologyCohort StudiesINTERFERON; HEPATITIS C; CIRRHOSIS; CHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; SUSTAINED VIROLOGICAL RESPONSE; Liver cirrhosis.MedicinegeneticsLongitudinal StudiesViralCIRRHOSISHazard ratiovirus diseasesHepatitis CAdult Antiviral Agents; therapeutic use Cohort Studies Female Hepacivirus; genetics Hepatitis C; blood/complications/drug therapy/mortality Humans Interferon-alpha; therapeutic use Liver Cirrhosis; drug therapy/mortality/virology Longitudinal Studies Male Middle Aged Multivariate Analysis RNA; Viral; blood Retrospective Studies Survival Analysis Treatment OutcomeMiddle AgedLiver cirrhosis.Treatment OutcomeSUSTAINED VIROLOGICAL RESPONSEHEPATITIS CLiver Cirrhosis/drug therapy Liver Cirrhosis/virologyRNA ViralFemaleAdultINTERFERONmedicine.medical_specialtyCHRONIC HEPATITIS CAntiviral AgentsbloodInternal medicineHumansRetrospective StudiesSustained virological response interferon-alpha HCV-related cirrhosis:Hepatologybusiness.industryProportional hazards modelInterferon-alphaRetrospective cohort studyblood/complications/drug therapy/mortalityHepatologymedicine.diseaseSurvival Analysisdigestive system diseasesDiscontinuationSurgerytherapeutic useMultivariate AnalysisRNAbusiness
researchProduct

Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.

2019

Abstract Introduction and objectives Non-alcoholic steatohepatitis (NASH) indication of liver transplant (LT) has increased recently, whereas alcoholic cirrhosis remains a major indication for LT. To characterize NASH-related cases and to compare the post-transplant outcome of these two conditions represents our major objective. Material and methods Patients undergoing LT for NASH between 1997 and 2016 were retrieved. Those transplanted between 1997 and 2006 were compared to an “age and LT date” matched group of patients transplanted for alcoholic cirrhosis (ratio 1:2). Baseline features and medium-term outcome measures were compared. Results Of 1986 LT performed between 1997 and 2016, 40 (…

Liver CirrhosisMaleAlcoholic liver diseaseCirrhosisHepatocellular carcinomamedicine.medical_treatmentSpecialties of internal medicineLiver transplantationGastroenterologyCohort Studies0302 clinical medicinePostoperative ComplicationsLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseCause of DeathHyperuricemiaRenal InsufficiencyCardiovascular risk factorsIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951Cardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaHypertension030211 gastroenterology & hepatologyFemaleAlcoholAdultmedicine.medical_specialtyCarcinoma HepatocellularHyperuricemia03 medical and health sciencesYoung AdultInternal medicinemedicineDiabetes MellitusHumansObesityAgedDyslipidemiasRetrospective StudiesHepatologybusiness.industrynutritional and metabolic diseasesOverweightmedicine.diseasedigestive system diseasesLiver TransplantationSpainSteatohepatitisNeoplasm Recurrence LocalbusinessDyslipidemiaAnnals of hepatology
researchProduct

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombo…

2015

Background: A 24-48-week course of interferon-based therapy poorly tolerated in hepatitis C virus (HCV) cirrhosis patients with thrombocytopenia. Aim of the study was to identify patients at low-risk of liver-related complications over a 12-week course of interferon-based therapy. Methods: We assessed the rate of complications and death during the first 12 weeks of interferon-based therapy in HCV cirrhotics with thrombocytopenia (platelets ≤75×109/L) enrolled in the ENABLE-1 and -2 phase 3 randomised controlled trials. Results: Overall, among 1441 patients, 89 complications (6.9%) and 10 deaths (0.7%) were observed within the first 12 weeks of therapy. At univariate analysis baseline albumi…

Liver CirrhosisMaleCirrhosisHepacivirusmedicine.disease_causeGastroenterologyBenzoatesSeverity of Illness IndexLiver-related complicationchemistry.chemical_compoundModel for End-Stage Liver DiseaseRisk FactorsAlbumin levelHydrazineMultivariate AnalysiAged 80 and overUnivariate analysisGastroenterologyHepatitis CMiddle AgedHydrazinesTreatment OutcomeFemaleHumanAdultmedicine.medical_specialtyLiver CirrhosiHepatitis C virusEltrombopagAlpha interferonAntiviral AgentsBenzoateInternal medicineAlbuminsRibavirinmedicineHumansLiver-related mortalityAgedAntiviral AgentHepaciviruHepatologybusiness.industryAlbuminRisk FactorRibavirinMELD scoreInterferon-alphaHepatitis C Chronicmedicine.diseaseThrombocytopeniaSurgerychemistryPyrazoleMultivariate AnalysisPyrazolesbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study

2017

Background & Aims: Metabolic syndrome (MS) and its individual components are associated with the severity and progression of nonalcoholic fatty liver disease (NAFLD). We sought to evaluate the relationship between MS components and the risk of severe hepatic fibrosis in NAFLD patients discriminated by age. Methods: We considered 863 consecutive patients with biopsy-proven NAFLD, who had been fully evaluated for components of MS. Results: Multivariate logistic regression analysis showed that F3-F4 was associated with visceral obesity, IFG/diabetes, and low high-density lipoprotein (HDL) cholesterol, but not triglycerides >150 or arterial hypertension. A significant interaction was found betw…

Liver CirrhosisMaleGastroenterologyBody Mass Index0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver disease10. No inequalityDiabetesAge FactorsMiddle AgedMetabolic syndrome3. Good healthItalyLiver030220 oncology & carcinogenesisObesity Abdominal030211 gastroenterology & hepatologyFemaleWaist CircumferenceLipoproteins HDLAdultmedicine.medical_specialtyDiabetes Complications03 medical and health sciencesDiabetes mellitusInternal medicinemedicineHumansNonalcoholic fatty liver diseaseObesityAgedDiabetes; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; HepatologyHepatologybusiness.industrynutritional and metabolic diseasesHepatologymedicine.diseaseObesityMiddle ageCross-Sectional StudiesLogistic ModelsdiabeteMultivariate AnalysisMetabolic syndromeInsulin ResistanceHepatic fibrosisbusiness
researchProduct

Clinical aspects of bleeding complications in cirrhotic patients

2000

Liver disease is a frequent cause of haemostatic abnormalities, which may lead to overt or occult bleeding. Clinical manifestations of hepatic coagulopathy include upper and lower gastrointestinal haemorrhage, easy bruising and bleeding from gums, nose or the female genital tract. The most significant bleeding problem among patients with chronic liver disease is blood loss due to portal hypertension. About 30% of subjects with oesophageal or gastric varices resulting from cirrhosis have an episode of gastrointestinal bleeding in their lifetime. Risk factors for the first episode of variceal bleeding include the severity of liver dysfunction, large varices, and the presence of endoscopic red…

Liver CirrhosisMaleGastrointestinal bleedingmedicine.medical_specialtyCirrhosisBiopsyDysfunctional uterine bleedingHemorrhageFactor VIIaChronic liver diseasePostoperative ComplicationsmedicineHumansFirst episodebusiness.industryBacterial InfectionsHematologyGeneral MedicineGastric varicesmedicine.diseaseRecombinant ProteinsSurgeryPortal hypertensionFemalemedicine.symptombusinessVaricesBlood Coagulation & Fibrinolysis
researchProduct

The abdominal wall hernia in cirrhotic patients: A historical challenge

2018

Abstract Background The incidence rate of abdominal wall hernia is 20–40% in cirrhotic patients. A surgical approach was originally performed only if complication signs and symptoms occurred. Several recent studies have demonstrated the usefulness of elective surgery. During recent decades, the indications for surgical timing have changed. Methods Cirrhotic patients with abdominal hernia who underwent surgical operation for abdominal wall hernia repair at the Policlinico “Paolo Giaccone” at Palermo University Hospital between January 2010 and September 2016 were identified in a prospective database, and the data collected were retrospectively reviewed; patients’ medical and surgical records…

Liver CirrhosisMaleHerniaAbdominal wall hernia; Cirrhosis; Emergency; Risk factors; Surgery; Surgery; Emergency Medicinemedicine.medical_treatmentAbdominal Hernia030230 surgerylaw.inventionAbdominal wallPostoperative Complications0302 clinical medicinelawAscitesMedicineProspective StudiesAged 80 and overlcsh:Medical emergencies. Critical care. Intensive care. First aidMiddle AgedHernia repairIntensive care unitTreatment Outcomemedicine.anatomical_structureCirrhosisElective Surgical ProceduresEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.symptomResearch Articlemedicine.medical_specialtylcsh:SurgeryRisk Assessment03 medical and health sciencesHumansHerniaElective surgeryHerniorrhaphyAgedRetrospective StudiesCirrhosibusiness.industryAbdominal Walllcsh:RD1-811lcsh:RC86-88.9medicine.diseaseSurgeryRisk factorsEmergencyAbdominal wall herniaSurgeryRisk factorbusinessComplication
researchProduct

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

2008

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis trea…

Liver CirrhosisMalePathologyCirrhosisAdult Antibodies; Viral; blood Carcinoma; Hepatocellular; blood/pathology/virology Cohort Studies Female Hepatitis B Core Antigens; immunology Hepatitis B virus; immunology Hepatitis C; blood/complications/pathology Humans Liver Cirrhosis; blood/etiology/pathology Liver Neoplasms; blood/pathology/virology Male Middle Aged Retrospective Studies Risk FactorsAntibodies ViralGastroenterologyanti HBcCohort StudiesimmunologyRisk FactorsHBVViralHCCCIRRHOSISLiver NeoplasmsGastroenterologyvirus diseasesHBV HCV COINFECTIONMiddle AgedHepatitis B Core AntigensHepatitis CAdult; Antibodies Viral; Carcinoma Hepatocellular; Cohort Studies; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; GastroenterologyHepatocellular carcinomaHCVFemaleAdultmedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularblood/pathology/virologyAntibodiesbloodblood/complications/pathologyInternal medicinemedicineHumansIn patientHEPATOCELLULAR CARCINOMAHEPATOCELLULAR CARCINOMA; HCV; HBV; CIRRHOSIS; HBV HCV COINFECTIONRetrospective StudiesHepatologybusiness.industryCarcinomaCancerHepatocellularmedicine.diseasedigestive system diseasesblood/etiology/pathologybusiness
researchProduct